A single-dose of the respiratory syncytial virus (RSV) vaccine in older adults showed waning efficacy across three seasons of the virus. A booster dose one year after the initial shot failed to do ...

A landmark global trial shows that one dose of the RSVPreF3 OA vaccine protects older adults against serious RSV lung disease for three seasons, raising hopes for long-term protection with just a ...

Most cases are mild. But some children are more likely to get seriously ill, including: Each year, RSV sends more than 57,000 children to the hospital. When adults and older children catch RSV ...

All three vaccines are approved for use in the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults ages ≥60 years. In addition, Arexvy is approved for prevention of LRTD ...

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC ...

The European Commission approved Pfizer's (PFE.N), opens new tab respiratory syncytial virus vaccine for the prevention of lower respiratory tract disease caused by RSV in adults aged 18 to 59 at ...

Due to a law enacted in 2023, Medicare now covers the RSV vaccine for older adults under Part D, which typically covers prescription drugs. This means you shouldn’t incur any out-of-pocket costs.

ABRYSVO is the first and only RSV vaccine approved in the European Union (EU) for non-pregnant adults aged 18-49 Active immunization of individuals 18 years of age and older for the prevention of ...

NEW YORK, April 01, 2025--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing authorization for ABRYSVO ®, the ...